No headlines found.
PRNewswire (Thu, 16-Apr 8:30 AM ET)
Greenland Mines Subsidiary Major Precious Greenland A/S Joins Greenland Business Association
PRNewswire (Thu, 2-Apr 12:01 PM ET)
Greenland Mines Secures Icebreaker Argus For 2026 Skaergaard Field Program
PRNewswire (Wed, 25-Mar 8:00 AM ET)
Greenland Mines Secures Additional 180-Day Period for Nasdaq Bid Price Compliance
PRNewswire (Mon, 23-Mar 8:00 AM ET)
PRNewswire (Thu, 19-Mar 12:05 PM ET)
PRNewswire (Thu, 12-Mar 10:28 AM ET)
Greenland Mines Ltd develops essential medicines for the treatment of chronic diseases - cancer, cardiovascular, and neurodegenerative disorders. The Company operates as a single reporting segment focused on developing essential medicines for these chronic diseases. The Company has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and proprietary patented technologies involving melanocortin receptor-binding molecules and a gene therapy platform that introduces a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases.
Greenland Mines trades on the NASDAQ stock market under the symbol GRML.
As of April 17, 2026, GRML stock price climbed to $0.42 with 5,103,254 million shares trading.
GRML has a market cap of $50.92 million. This is considered a Micro Cap stock.
The top ETF exchange traded funds that GRML belongs to (by Net Assets): VXF.
GRML support price is $.36 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRML shares will trade within this expected range on the day.